Physician profile
Wei Zhang
NPI 1821445016
$2,037.49
in general payments reported to CMS, 2019-2025
22 companies · $892 in 2025
The $892 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $169 · 2020: $17.90 · 2021: $60.38 · 2022: $105 · 2023: $339 · 2024: $454 · 2025: $892.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,685.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,685.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $321.78 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Dexcom, INC. | $302.92 | 2023-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Corcept Therapeutics | $235.80 | 2025 | Korlym |
| Novo Nordisk INC | $162.61 | 2022-2025 | Ozempic, Rybelsus |
| Xeris Pharmaceuticals, INC. | $153.09 | 2023-2025 | Gvoke Hypopen, Recorlev |
| Madrigal Pharmaceuticals | $132.70 | 2025 | Rezdiffra |
| Recordati_rare_diseases_inc. | $117.43 | 2025 | Isturisa |
| Amryt Pharma Holdings Ltd | $99.05 | 2022-2023 | Mycapssa |
| Astrazeneca Pharmaceuticals Lp | $89.91 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $80.83 | 2019 | |
| Medtronic, INC. | $43.44 | 2024 | Minimed 780g |
| Neurocrine Biosciences, INC. | $42.98 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $39.13 | 2021-2022 | |
| Ascensia Diabetes Care US INC. | $36.90 | 2024 | |
| Alexion Pharmaceuticals, INC. | $29.65 | 2025 | Strensiq |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sequel Med Tech, LLC | $28.37 | 2025 | Twiist |
| Averitas Pharma INC. | $28.29 | 2025 | Qutenza |
| Beta Bionics, INC. | $24.10 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Insulet Corporation | $18.61 | 2025 | Omnipod |
| United Therapeutics Corporation | $18.41 | 2021 | |
| Boston Scientific Corporation | $17.90 | 2020 | |
| Janssen Pharmaceuticals, INC | $13.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wei Zhang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.